RECURSION PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $74.7M | $58.8M | $44.6M | $39.8M | $10.2M |
| Cost of revenue | $71.0M | $45.2M | $42.6M | $48.3M | $0 |
| Research and development | $475.3M | $314.4M | $241.2M | $155.7M | $135.3M |
| Operating expenses | — | — | — | — | $193.0M |
| Operating income | -$648.1M | -$479.0M | -$350.1M | -$245.7M | -$182.8M |
| Interest expense | $1.8M | $1.6M | $97,000 | $55,000 | $3.0M |
| Pretax income | -$644.9M | -$464.8M | -$332.1M | -$239.5M | -$186.5M |
| Income tax expense | -$136,000 | -$1.1M | -$4.1M | $0 | $0 |
| Net income | -$644.8M | -$463.7M | -$328.1M | -$239.5M | -$186.5M |
| Balance Sheet | |||||
| Cash and equivalents | $743.3M | $594.4M | $391.6M | $549.9M | $285.1M |
| Current assets | $812.8M | $714.3M | $438.1M | $569.8M | $534.7M |
| Total assets | $1.5B | $1.4B | $653.7M | $701.3M | $610.3M |
| Current liabilities | $147.7M | $187.5M | $93.2M | $100.3M | $46.7M |
| Total liabilities | $343.3M | $413.8M | $190.3M | $215.5M | $67.4M |
| Stockholders' equity | $1.1B | $1.0B | $463.4M | $485.8M | $542.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$371.8M | -$359.2M | -$287.8M | -$83.5M | -$158.6M |
| Depreciation and amortization | $83.7M | $36.5M | $24.4M | $11.8M | $8.4M |
| Stock-based compensation | $111.2M | $81.7M | $53.5M | $27.9M | $14.8M |
| Capital expenditure | $6.5M | $13.7M | $12.0M | $37.1M | $39.8M |
| Free cash flow | -$378.3M | -$372.9M | -$299.7M | -$120.6M | -$198.4M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 529.9M · Free float 93.1%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.